Pancreatic Cancer Research

ResearcherQueen Mary University of LondonActive in the last 2 years

Lewis G. Stevens

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0373-4272; OpenAlex author ID A5043021954. Sources: OpenAlex.

Their work

Papers
2 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

  1. Is oncolytic adenoviral-mediated immunotherapy through p53-overexpression the solution to refractory pancreatic ductal adenocarcinoma? First author DOI 10.1080/17474124.2024.2363222↗
  2. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. Co-author DOI 10.1111/hpb.12355↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lucy J. A. Harriss · 1 shared paper, 2024 · strength 0.26
  2. Nicola E. Annels · 1 shared paper, 2024 · strength 0.26
  3. Adam Enver Frampton · 1 shared paper, 2024 · strength 0.26
  4. Samir Pathak · 1 shared paper, 2015 · strength 0.06
  5. Sanjay Pandanaboyana · 1 shared paper, 2015 · strength 0.06
  6. Andrew Malvern Smith · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.